Rhumbline Advisers Acquires 5,215 Shares of Kura Oncology, Inc. $KURA

Rhumbline Advisers lifted its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 5.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 105,206 shares of the company’s stock after purchasing an additional 5,215 shares during the period. Rhumbline Advisers owned 0.12% of Kura Oncology worth $694,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Kura Oncology during the first quarter worth about $139,000. Jacobs Levy Equity Management Inc. grew its position in Kura Oncology by 57.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,544,113 shares of the company’s stock worth $10,191,000 after buying an additional 566,193 shares in the last quarter. Hsbc Holdings PLC grew its position in Kura Oncology by 26.5% during the first quarter. Hsbc Holdings PLC now owns 54,491 shares of the company’s stock worth $351,000 after buying an additional 11,406 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Kura Oncology by 7.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock worth $1,147,000 after buying an additional 9,050 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in Kura Oncology during the fourth quarter worth about $130,000.

Kura Oncology Stock Performance

KURA stock opened at $8.25 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. The company has a 50 day moving average price of $7.13 and a 200 day moving average price of $6.60. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.40. The stock has a market capitalization of $716.08 million, a PE ratio of -3.65 and a beta of 0.19.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to analysts’ expectations of $64.95 million. Analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In related news, CEO Troy Edward Wilson acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was acquired at an average cost of $8.20 per share, with a total value of $410,000.00. Following the completion of the purchase, the chief executive officer directly owned 100,968 shares in the company, valued at approximately $827,937.60. This trade represents a 98.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KURA. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 26th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research note on Friday, June 20th. JMP Securities cut their price target on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating for the company in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, Guggenheim initiated coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They set a “neutral” rating for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $24.10.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.